Almirall Aesthetics Takeover

Dermatology focused Almirall has announced that it will be exercising a call option to acquire 100% of aesthetics technology company ThermiGen LLC. Almirall plans to complete the acquisition by Jan. 31st 2016, with hopes to create a profile in the aesthetics market to strengthen its presence in derma.

Dermatology focused Almirall has announced that it will be exercising a call option to acquire 100% of aesthetics technology company ThermiGen LLC. Almirall plans to complete the acquisition by Jan. 31st 2016, with hopes to create a profile in the aesthetics market to strengthen its presence in derma.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By 

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

 

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.

UPDATED: Merck KGaA Seals SpringWorks Buy

 
• By 

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

In Brief: Mosaic Gains Two Clinical-Stage Oncology Assets From Astex

 

Mosaic Therapeutics has in-licensed two clinical-stage oncology assets from Astex Pharmaceuticals to develop proprietary combination therapies for hard-to-treat cancers. The deal includes up to a 22% equity stake for Astex, future revenue sharing, and a planned clinical study in 2026.

More from Business

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By 

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Another CRL Prompts Questions About Regeneron’s Regulatory Operations

 

CEO Len Schleifer explained on the company’s Q1 earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.